spacer
NIDDK Small
Business Home
Research Funding Resources News & Events Program Statistics FAQs

SBIR & STTR Program Statistics

SBIR & STTR grants are one of several mechanisms by which the NIDDK supports translation of basic science discoveries or inventions into clinical practice. The NIDDK has a diversified SBIR/STTR portfolio, reflecting the breadth of its mission. In Fiscal Year 2018 (FY18) NIDDK made 85 new competing grants and extension grants (Phase II of Fast-Track) spanning therapeutics, devices, diagnostics, research tools, software, and more. SBIR & STTR awards are paid out of a set-aside share of the NIDDK budget (3.2% for SBIR and 0.45% for STTR in FY18).

Distribution of NIDDK SBIR & STTR Awards Made in FY18 by Category:

  • Therapeutic agent (e.g., small molecules, biologics), 48%
  • Diagnostic (e.g., in vitro diagnostics, imaging techniques, contrast agents), 20%
  • Device, 18%
  • Research Tool, 7%
  • Software and Health IT, 7%

Additional details regarding specific projects supported by the SBIR and STTR programs can be found in NIH RePORTER.

Beyond Phase I and Phase II, the NIDDK supports Fast-Track, Phase IIB, and, Direct-to-Phase II awards (SBIR only). The NIDDK grants Phase IIB awards that resemble Phase II in terms of dollar-amount and length. Eligible applicants propose to continue the process of developing technologies that ultimately require:

  • Clinical evaluation
  • Approval by a Federal regulatory agency
  • Continuing refinements to durable medical equipment (DME) designs such as cost reduction, testing for safety, durability, and reliability, and meeting or establishing standards

Additional details regarding NIDDK's Phase IIB program can be found in the current Program Descriptions and Research Topics Document, which can be found on the NIH SBIR Funding page. These grants help to bridge the proverbial gap between early-stage technology--supported by Phase I and II--and the commercialization of a market-ready technology--typically supported by other sources, including venture capital and industrial partners. Success rates for Phase IIB resemble those of Phase II (see NIH SBIR/STTR Award Data and click on 'Success Rates of SBIR/STTR Applications by Phase').